A Phase 1 of CTX-8371 in Patients With Advanced Malignancies

Launched by COMPASS THERAPEUTICS · Nov 27, 2023

Keywords

ClinConnect Summary

This clinical trial is studying a new treatment called CTX-8371 for patients with advanced cancers, including non-small cell lung cancer, triple-negative breast cancer, Hodgkin lymphoma, head and neck squamous cell carcinoma, and malignant melanoma. It is a Phase 1 trial, which means it's the first time this treatment is being tested in humans. The trial is designed to find out how much of the drug is safe to give and how well it works. Participants will be placed in one of two groups: one will gradually receive increasing doses of the drug to find the best amount, and the other will receive a set dose to see how it performs.

To be eligible for the trial, participants must be at least 18 years old and have a confirmed diagnosis of one of the targeted cancers that has not responded to standard treatments. They should have measurable disease and meet certain health criteria, such as having good bone marrow, liver, and kidney function. Participants can expect to receive CTX-8371 as their only treatment during the study and will be closely monitored for any side effects. The trial is currently recruiting patients, and those interested should consult with their healthcare provider to see if they qualify. This study offers a potential new option for patients whose current treatments have not been effective.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Age 18 years or older
• • 2. Patients must have a histologically or cytologically confirmed diagnosis of locally advanced unresectable or metastatic disease that is relapsed/refractory to standard therapy or for which no effective standard therapy is available, including
• • 1. Malignant Melanoma (MM)
• • Patients who have progressed after a minimum of 2 doses of a PD-1/PD-L1 treatment. Study enrollment (C1D1) must be within 12 weeks of the last dose of the anti-PD-1/PD-L1 blocking antibody.
• • Patients must have had prior testing for BRAF V600 mutations.- Patients with BRAF V600 activating mutation must have received prior therapy with a BRAF/MEK inhibitor.
• • Uveal and mucosal melanoma are excluded.
• • 2. Head and Neck squamous cell carcinoma (HNSCC)
• • HNSCC of oral cavity, oropharynx, hypopharynx, or larynx
• • Patients who have progressed after a minimum of 2 doses of a PD-1/PD-L1 treatment. Study enrollment (C1D1) must be within 12 weeks of the last dose of the anti-PD-1/PD-L1 blocking antibody.
• • Patients must have received prior treatment with platinum-based chemotherapy.
• • 3. Non-Small Cell Lung Cancer (NSCLC)
• • Patients who have progressed after a minimum of 2 doses of a PD-1/PD-L1 treatment. Study enrollment (C1D1) must be within 12 weeks of the last dose of the anti-PD-1/PD-L1 blocking antibody.
• • Patients must have received prior treatment with platinum-based chemotherapy.
• • 4. Triple Negative Breast Cancer (TNBC)
• • ER/PR and HER2 status should be defined by ASCO/CAP guidelines (JCO Allison et al 2020).
• • Patients with HER2-low cancers (IHC 1+ or FISH-negative) are excluded.
• • Patients must have received prior sacituzumab govitecan and if PD-L1 ≥10% by CPS pembrolizumab with chemotherapy.
• • 5. Classical Hodgkin Lymphoma (HL)
• • Patients must have received at least two prior systemic therapies including brentuximab vedotin (if eligible) and a prior PD-1 inhibitor
• • Patients must have experienced less than a CR (according to Lugano criteria to anti- PD-1 treatment
• • 3. Patients with NSCLC, MM, TNBC, and HNSCC must have measurable disease per RECIST 1.1. Patients with HL must have at least one measurable lesion \> 1.5 cm for nodal, \> 1.0 cm for extranodal FDG-avid disease by the Lugano (2014) response criteria. Tumor sites that are considered measurable must not have received prior radiation
• • 4. Eastern Cooperative Oncology Group (ECOG) performance status 0-1
• • 5. Adequate bone marrow function defined by absolute neutrophil (ANC) of ≥ 1.5×109/L, platelet count of ≥ 100.0×109/L, and hemoglobin of ≥ 9.0 g/dL (with or without transfusion)
• • 6. Adequate hepatic function defined as serum total bilirubin ≤ 1.5 × ULN, AST/ALT ≤ 2.5 × ULN (or ≤ 5 × ULN in patients with liver metastases)
• • 7. Adequate renal function defined as creatinine clearance ≥ 30mL/min by Cockcroft-Gault equation
• • 8. Female patients must be surgically sterile (or have a monogamous partner who is surgically sterile) or be at least 2 years postmenopausal or commits to use 2 acceptable forms of birth control (defined as the use of an intrauterine device (IUD), a barrier method with spermicide, condoms, any form of hormonal contraceptives) or abstinence for the duration of the study and for 4 months following the last dose of study treatment. Male patients must be sterile (biologically or surgically) or commit to the use of a reliable method of birth control (condoms with spermicide) for the duration of the study and for 4 months following the last dose of study treatment.
• • 9. Female patients who are women of childbearing potential (WOCBP) must have a negative serum pregnancy test at Screening within 7 days of dosing with CTX-8371
• • 10. Last dose of previous PD-1 or PD-L1 therapy ≥ 28 days, other anticancer therapy \> 21 days (or 2 half-lives for proteins, whichever is longer), radiotherapy \>21 days (concurrent localized palliative radiotherapy is allowed during CTX-8371 treatment), or surgical intervention \>21 days prior to the first dose of CTX-8371
• • 11. Resolution of all prior anti-cancer therapy toxicities ≤ Grade 2
• • 12. Capable of understanding and complying with protocol requirements
• • 13. Signed and dated institutional review board (IRB)/independent ethics committee (IEC)-approved informed consent form (ICF) before any protocol-directed screening procedures are performed
• Exclusion Criteria:
• • 1. Developed clinically significant adverse reaction to PD-1 or PD-L1 therapy, including immune related adverse reactions, which led to discontinuation of treatment
• • 2. Systemic therapy with immunosuppressive agents within 7 days before the start of CTX-8371 treatment. Topical, intranasal, intraocular, or inhaled corticosteroids and physiologic replacement for patients with adrenal insufficiency are allowed
• • 3. Patient is a pregnant or lactating WOCBP
• • 4. Prior organ transplantation
• • 5. Patients with evidence of active hepatitis B virus (HBV), hepatitis C virus (HCV) or human immunodeficiency virus (HIV) infection. Patients with positive HBsAg and/or detectable HBV DNA are eligible only if adequately controlled on antiviral therapy according to institutional standards and liver function eligibility criteria are also met. HCV patients showing sustained viral response or patients with immunity to HBV infection may enroll.
• • 6. Active autoimmune disease or medical conditions requiring chronic steroid (i.e., \> 10 mg/day prednisone or equivalent) or immunosuppressive therapy. Patients with a prior history of autoimmune disease may be eligible following discussion with the Medical Monitor
• 7. Other medical condition that in the opinion of the Investigator and/or Sponsor Medical Monitor may interfere with the conduct and/or interpretation of the current study, including:
• • 1. Congestive heart failure (\> New York Heart Association Class II), active coronary artery disease, unevaluated new onset angina within 3 months or unstable angina (angina symptoms at rest) or clinically significant cardiac arrhythmias
• • 2. QTc interval (using Fridericia correction calculation) \> 480 msec